Fungal brain infections

Current Opinion in Neurology

Volumn 21, Issue 3, 2008, Pages 347-352

  Scully, Eileen P ^a   Baden, Lindsey R ^a   Katz, Joel T ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Aspergillus; Candida; Central nervous system; Fungi; Mycoses

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN B; CASPOFUNGIN; CIMETIDINE; CYCLOSPORIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; NYSTATIN; PHENYTOIN; POSACONAZOLE; RAVUCONAZOLE; RIFABUTIN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; BLASTOMYCES; BLASTOMYCOSIS; BONE MARROW SUPPRESSION; BRAIN BIOPSY; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID; COCCIDIOIDES; CORTICOSTEROID THERAPY; CRYPTOCOCCUS NEOFORMANS; HALLUCINATION; HISTOPATHOLOGY; HISTOPLASMA CAPSULATUM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; LEUKEMIA; LIVER TOXICITY; NEUTROPENIA; NONHUMAN; POPULATION RISK; REVIEW; RISK FACTOR; SIDE EFFECT; VISUAL DISORDER;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CENTRAL NERVOUS SYSTEM FUNGAL INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; RISK FACTORS;

EID: 43249090085     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3282fee95b     Document Type: Review

References (51)

1. Black KE, Baden LR. Fungal infections of the CNS: treatment strategies for the immunocompromised patient. CNS Drugs 2007; 21:293-318. This is a comprehensive review of the CNS pharmacology of antifungal agents, including spectrum of activity, pharmacokinetics, side effects and drug-drug interactions.
2. Chakrabarti A. Epidemiology of central nervous system mycoses. Neurol India 2007; 55:191-197. This study pools relevant case series of CNS fungal infections to categorize the relative frequencies of individual fungal pathogens in specific populations at risk.
3. Murthy JM. Fungal infections of the central nervous system: the clinical syndromes. Neurol India 2007; 55:221-225.
4. Amrutkar PP, Rege MD, Chen H, et al. Comparison of risk factors for candidemia versus bacteremia in hospitalized patients. Infection 2006; 34:322-327.
5. Sanchez-Portocarrero J, Perez-Cecilia E, Corral O, et al. The central nervous system and infection by Candida species. Diagn Microbiol Infect Dis 2000; 37:169-179.
6. Pagano L, Girmenia C, Mele L, et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica 2001; 86:862-870.
7. Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100:4358-4366.
8. Hagen EA, Stern H, Porter D, et al. High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin Infect Dis 2003; 36:9-15.
9. Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am 2003; 17:113-134.
10. Blair JE. Coccidioidomycosis in patients who have undergone transplantation. Ann N Y Acad Sci 2007; 1111:365-376.
11. Herring AC, Lee J, McDonald RA, et al. Transient neutralization of tumor necrosis factor alpha can produce a chronic fungal infection in an immunocompetent host: potential role of immature dendritic cells. Infect Immun 2005; 73:39-49.
12. Wood KL, Hage CA, Knox KS, et al. Histoplasmosis after treatment with antitumor necrosis factor-alpha therapy. Am J Respir Crit Care Med 2003; 167:1279-1282.
13. Filler SG, Yeaman MR, Sheppard DC. Tumor necrosis factor inhibition and invasive fungal infections. Clin Infect Dis 2005; 41 (Suppl 3):S208-S212.
14. Munoz P, Giannella M, Valerio M, et al. Cryptococcal meningitis in a patient treated with infliximab. Diagn Microbiol Infect Dis 2007; 57:443-446.
15. McCarthy KM, Morgan J, Wannemuehler KA, et al. Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence. AIDS 2006; 20:2199-2206.
16. Mirza SA, Phalen M, Rimland D, et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis 2003; 36:789-794.
17. Wheat J. Endemic mycoses in AIDS: a clinical review. Clin Microbiol Rev 1995; 8:146-159.
18. Pappas PG, Pottage JC, Powderly WG, et al. Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1992; 116:847-853.
19. Rees JR, Pinner RW, Hajjeh RA, et al. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. Clin Infect Dis 1998; 27:1138-1147.
20. Davis JA, Costello DJ, Venna N. Laboratory investigation of fungal infections of the central nervous system. Neurol India 2007; 55:233-240.
21. Satishchandra P, Mathew T, Gadre G, et al. Cryptococcal meningitis: clinical, diagnostic and therapeutic overviews. Neurol India 2007; 55:226-232.
22. Jarvis JN, Harrision TS. HIV-associated cryptococcal meningitis. AIDS 2007; 18:2119-2129.
23. Baddley JW, Salzman D, Pappas PG. Fungal brain abscess in transplant recipients: epidemiologic, microbiologic and clinical features. Clin Transpl 2002; 16:419-424.
24. Warnock DW. Trends in the epidemiology of invasive fungal infections. Nippon Ishinkin Gakkai Zasshi 2007; 48:1-12. This study summarizes and interprets epidemiological evidence of changing trends in invasive fungal infections.
25. Kleinschmidt-DeMasters BK. Central nervous system aspergillosis: a 20-year retrospective series. Hum Pathol 2002; 33:116-124.
26. Jain KK, Mittal SK, Kumar S, Gupta RK. Imaging features of central nervous system fungal infections. Neurol India 2007; 55:241-250.
27. Ostrow TD, Hudgins PA. Magnetic resonance imaging of intracranial fungal infections. Top Magn Reson Imaging 1994; 6:22-31.
28. Carrazana EJ, Rossitch E Jr, Morris J. Isolated central nervous system aspergillosis in the acquired immunodeficiency syndrome. Clin Neurol Neurosurg 1991; 93:227-230.
29. O'Shaughnessy EM, Shea YM, Witebsky FG. Laboratory diagnosis of invasive mycoses. Infect Dis Clin North Am 2003; 17:135-158.
30. Connolly PA, Durkin MM, Lemonte AM, et al. Improvement in the detection of Histoplasma antigen by a quantitative enzyme immunoassay. Clin Vaccine Immunol 2007; 10.
31. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41:654-659.
32. Pickering JW, Sant HW, Bowles CA, et al. Evaluation of a (1→3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43:5957-5962.
33. Viscoli C, Machetti M, Gazzola P, et al. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol 2002; 40:1496-1499.
34. Redmond A, Dancer C, Woods ML. Fungal infections of the central nervous systems: a review of fungal pathogens and treatment. Neurol India 2007; 55:251-259.
35. Groll AH, Gea-Banacloche JC, Glasmacher A, et al. Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 2003; 17:159-191.
36. Alexander BD, Wingard JR. Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis 2005; 40 (Suppl 6):S414-S421.
37. Schwartz S, Ruhnke M, Ribaud P, et al. Poor efficacy of amphotericin B-based therapy in CNS aspergillosis. Mycoses 2007; 50:196-200.
38. Gubbins PO, Krishna G, Sansone-Parsons A, et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 2006; 50:1993-1999.
39. Sansone-Parsons A, Krishna G, Calzetta A, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006; 50:1881-1883.
40. Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12:552-559.
41. Bicanic T, Harrison T, Niepieklo A, et al. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 2006; 43:1069-1073.
42. Almyroudis NG, Sutton DA, Fothergill AW, et al. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007; 51:2587-2590.
43. Greenberg RN, Mullane K, van Burik JAH, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50:126-133.
44. van Burik JA, Hare RS, Solomon HF, et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42:e61-e65.
45. Betts R, Glasmacher A, Maertens J, et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer 2006; 106:466-473.
46. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53:337-349.
47. Prabhu RM, Orenstein R. Failure of caspofungin to treat brain abscesses secondary to Candida albicans prosthetic valve endocarditis. Clin Infect Dis 2004; 39:1253-1254.
48. Okugawa S, Ota Y, Tatsuno K, et al. A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid. Scand J Infect Dis 2007; 39:344-346.
49. Ehrmann S, Bastides F, Gissot V, et al. Cerebral aspergillosis in the critically ill: two cases of successful medical treatment. Intensive Care Med 2005; 31:738-742.
50. Chowfin A, Tight R, Mitchell S. Recurrent blastomycosis of the central nervous system: case report and review. Clin Infect Dis 2000; 30:969-971.
51. Pasqualotto AC, Howard SJ, Moore CB, Denning DW. Flucytosine therapeutic monitoring: 15 years experience from the UK. J Antimicrob Chemother 2007; 59:791-793.